サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1298397

重症筋無力症治療市場：薬剤クラス別、年齢層別、流通チャネル別：世界の機会分析と産業予測、2023-2032年

Myasthenia Gravis Treatment Market By Drug class, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日: | 発行: Allied Market Research | ページ情報: 英文 263 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
重症筋無力症治療市場：薬剤クラス別、年齢層別、流通チャネル別：世界の機会分析と産業予測、2023-2032年
出版日: 2023年04月01日
発行: Allied Market Research
ページ情報: 英文 263 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

重症筋無力症治療の世界市場は、2022年に17億米ドルと評価され、2023年から2032年にかけてCAGR 6.5%で成長し、2032年には31億米ドルに達すると予測されています。

重症筋無力症（MG）は、抗体が神経筋接合部の受容体を攻撃・損傷し、筋力低下や疲労を引き起こす自己免疫疾患です。また、抗体は神経筋接合部のシナプス後膜に存在するタンパク質であるアセチルコリン受容体（AChR）を標的とします。さらに場合によっては、抗体は筋特異的キナーゼ（MuSK）など、アセチルコリン受容体（AChR）に関連する他のタンパク質を標的とすることもあります。その結果、神経と筋肉間の情報伝達が障害され、筋力低下や疲労が生じる。

重症筋無力症の最も一般的な症状には、特に目、顔、喉、手足の筋力低下、会話、嚥下、呼吸困難、眼瞼下垂、複視、活動時に悪化する疲労などがあります。現在、重症筋無力症の治療薬としては、アセチルコリンエステラーゼ阻害薬、コルチコステロイド、免疫抑制剤、免疫グロブリン静注（IVIg）、モノクローナル抗体などがあります。

Myasthenia Gravis Treatment Market-IMG1

重症筋無力症治療市場の成長を牽引する主な要因は、重症筋無力症に罹患する患者数の増加、自己免疫疾患の診断の進歩、重症筋無力症の治療選択肢の増加です。重症筋無力症の世界の有病率の上昇は、重症筋無力症治療市場の成長を促進する主な要因の1つです。例えば、重症筋無力症財団（Myasthenia Gravis Foundation of America）によると、米国では10万人中約14～20人が重症筋無力症に罹患しており、この病気は男性よりも女性に多いです。さらに、重症筋無力症の罹患率は世界的に増加しており、この疾患に対する効果的な治療法の需要を促進すると予想されています。

さらに、重症筋無力症の診断の増加は、市場の成長を促進すると予想されます。重症筋無力症はまれで、しばしば誤診される自己免疫疾患であり、神経筋接合部に影響を及ぼし、筋力低下や疲労を引き起こします。この病気は、症状が微妙であったり、人によって大きく異なるため、診断が難しい場合があります。しかし、診断技術の進歩により、重症筋無力症の診断がより正確かつタイムリーに行われるようになり、市場成長の原動力となっています。重症筋無力症の診断が急増したことで、効果的な治療法に対する需要が高まり、市場の成長が促進されました。重症筋無力症の症例がより多く確認され、早期に診断されるにつれて、疾患を管理し合併症を予防するための効果的な治療に対するニーズが高まっています。このため、重症筋無力症に対するより効果的な新しい治療法の研究開発への投資が増加しています。

さらに、診断の増加により、患者やヘルスケア専門家の間でこの疾患に対する認識が高まっています。さらに、重症筋無力症の治療に特化した臨床開発段階にある薬剤の数が増加していることも、市場の成長を後押しすると予想されます。重症筋無力症の罹患者数が増加の一途をたどる中、効果的な治療法の需要が高まり、革新的な治療法の必要性が生じています。この需要により、製薬会社や研究機関は、この疾患の新しい治療法の開発に投資するようになり、臨床試験はその安全性と有効性を検証するための重要なツールとなっています。そのため、重症筋無力症に焦点を当てた臨床試験の急増は、重症筋無力症に苦しむ患者に新しい改善された治療法を提供することで、重症筋無力症治療市場の成長を促進すると予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資ポケット
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競合の激しさ
  • 市場力学
    • 促進要因
      • 重症筋無力症の効果的な治療法の需要の高まり
      • 重症筋無力症の有病率の急増
      • 新薬の研究開発の進展
    • 阻害要因
      • 重症筋無力症の治療に伴う副作用と高コスト
    • 機会
      • 新興市場における成長機会
  • COVID-19市場への影響分析

第4章 重症筋無力症治療市場：薬剤クラス別

  • 概要
    • 市場規模および予測
  • モノクローナル抗体
    • 主要市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 静注用免疫グロブリン
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第5章 重症筋無力症治療市場：年齢層別

  • 概要
    • 市場規模および予測
  • 55歳以下
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 55歳以上
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析： 国別

第6章 重症筋無力症治療市場：流通チャネル別

  • 概要
    • 市場規模と予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • ドラッグストア・小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第7章 重症筋無力症治療市場：地域別

  • 概要
    • 市場規模・予測： 地域別
  • 北米
    • 主要動向と機会
    • 市場規模・予測：薬剤クラス別
    • 市場規模・予測：年齢層別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 米国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効クラス別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • カナダ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • メキシコ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
  • 欧州
    • 主要動向と機会
    • 市場規模・予測：薬効クラス別
    • 市場規模・予測：年齢層別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ドイツ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効クラス別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • フランス
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • 英国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • イタリア
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • スペイン
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • その他欧州
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効クラス別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
  • アジア太平洋地域
    • 主要動向と機会
    • 市場規模・予測：薬効分類別
    • 市場規模・予測：年齢層別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 日本
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • 中国
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • インド
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • その他アジア太平洋地域
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
  • ラテンアメリカ・中東・アフリカ
    • 主要動向と機会
    • 市場規模・予測：薬効分類別
    • 市場規模・予測：年齢層別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ラテンアメリカ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効クラス別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別
      • 中東・アフリカ
      • 主要市場動向、成長要因、機会
      • 市場規模・予測：薬効分類別
      • 市場規模・予測：年齢層別
      • 市場規模・予測：流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2022年

第9章 企業プロファイル

  • Zydus Lifesciences Limited
  • Novartis AG
  • AstraZeneca
  • Bausch Health Companies, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Octapharma AG
  • Astellas Pharma Inc.
  • Kedrion, SpA
  • F. Hoffmann-La Roche Ltd.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. MYASTHENIA GRAVIS TREATMENT MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MYASTHENIA GRAVIS TREATMENT MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MYASTHENIA GRAVIS TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 06. MYASTHENIA GRAVIS TREATMENT MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. MYASTHENIA GRAVIS TREATMENT MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. MYASTHENIA GRAVIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. MYASTHENIA GRAVIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. MYASTHENIA GRAVIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 18. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 19. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 21. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 22. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 37. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 38. UK MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 40. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 41. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 56. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 57. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 59. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 60. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 62. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 63. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 65. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 66. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. LAMEA MYASTHENIA GRAVIS TREATMENT MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 68. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 70. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 73. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 75. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 76. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 77. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 78. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 79. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 80. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 81. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 82. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 83. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 84. ASTRAZENECA: PRODUCT SEGMENTS
  • TABLE 85. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 86. ASTRAZENECA: KEY STRATERGIES
  • TABLE 87. BAUSCH HEALTH COMPANIES, INC.: KEY EXECUTIVES
  • TABLE 88. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT
  • TABLE 89. BAUSCH HEALTH COMPANIES, INC.: PRODUCT SEGMENTS
  • TABLE 90. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO
  • TABLE 91. CSL LIMITED: KEY EXECUTIVES
  • TABLE 92. CSL LIMITED: COMPANY SNAPSHOT
  • TABLE 93. CSL LIMITED: PRODUCT SEGMENTS
  • TABLE 94. CSL LIMITED: PRODUCT PORTFOLIO
  • TABLE 95. CSL LIMITED: KEY STRATERGIES
  • TABLE 96. GRIFOLS, S.A.: KEY EXECUTIVES
  • TABLE 97. GRIFOLS, S.A.: COMPANY SNAPSHOT
  • TABLE 98. GRIFOLS, S.A.: PRODUCT SEGMENTS
  • TABLE 99. GRIFOLS, S.A.: PRODUCT PORTFOLIO
  • TABLE 100. GRIFOLS, S.A.: KEY STRATERGIES
  • TABLE 101. OCTAPHARMA AG: KEY EXECUTIVES
  • TABLE 102. OCTAPHARMA AG: COMPANY SNAPSHOT
  • TABLE 103. OCTAPHARMA AG: PRODUCT SEGMENTS
  • TABLE 104. OCTAPHARMA AG: PRODUCT PORTFOLIO
  • TABLE 105. ASTELLAS PHARMA INC.: KEY EXECUTIVES
  • TABLE 106. ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 107. ASTELLAS PHARMA INC.: PRODUCT SEGMENTS
  • TABLE 108. ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 109. KEDRION, SPA: KEY EXECUTIVES
  • TABLE 110. KEDRION, SPA: COMPANY SNAPSHOT
  • TABLE 111. KEDRION, SPA: PRODUCT SEGMENTS
  • TABLE 112. KEDRION, SPA: PRODUCT PORTFOLIO
  • TABLE 113. KEDRION, SPA: KEY STRATERGIES
  • TABLE 114. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 115. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 116. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 117. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMYASTHENIA GRAVIS TREATMENT MARKET
  • FIGURE 10. MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR INTRAVENOUS IMMUNOGLOBULIN, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR BELOW 55 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR ABOVE 55 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MYASTHENIA GRAVIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. MYASTHENIA GRAVIS TREATMENT MARKET BY REGION, 2022
  • FIGURE 22. U.S. MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. INDIA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. LATIN AMERICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 41. COMPETITIVE DASHBOARD
  • FIGURE 42. COMPETITIVE HEATMAP: MYASTHENIA GRAVIS TREATMENT MARKET
  • FIGURE 43. TOP PLAYER POSITIONING, 2022
  • FIGURE 44. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 45. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 46. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 47. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. ASTRAZENECA: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. BAUSCH HEALTH COMPANIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. BAUSCH HEALTH COMPANIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. CSL LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. CSL LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. CSL LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 59. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. OCTAPHARMA AG: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 62. ASTELLAS PHARMA INC.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. ASTELLAS PHARMA INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 64. KEDRION, SPA: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 65. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 67. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A11194

The global myasthenia gravis treatment market was valued at $1.7 billion in 2022, and is projected to reach $3.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032.

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies that attack and damage the receptors at the neuromuscular junction, leading to muscle weakness and fatigue. In addition, the antibodies target the acetylcholine receptor (AChR), which is a protein located on the postsynaptic membrane of the neuromuscular junction. Moreover, in some cases, the antibodies may target other proteins related to the acetylcholine receptor (AChR), such as muscle-specific kinase (MuSK). This leads to impaired communication between the nerve and muscle, which results in muscle weakness and fatigue.

The most common symptoms of myasthenia gravis include muscle weakness, particularly in the eyes, face, throat & limbs, difficulty speaking, swallowing, or breathing, drooping eyelids, double vision, and fatigue that worsens with activity. Currently, there are several drugs available for the treatment of myasthenia gravis, such as acetylcholinesterase inhibitors, corticosteroids, immunosuppressants, intravenous immunoglobulin (IVIg), and monoclonal antibodies.

Myasthenia Gravis Treatment Market - IMG1

The major factor driving the growth of myasthenia gravis treatment market are increase in number of patients suffering from myasthenia gravis, advancements in diagnosis of autoimmune disorders, and rise in availability of treatment options for myasthenia gravis. The rise in prevalence of myasthenia gravis worldwide is one of the primary drivers for the growth of the myasthenia gravis treatment market. For instance, according to the Myasthenia Gravis Foundation of America, approximately 14 to 20 out of 100,000 people in the U.S. are affected by myasthenia gravis, and the disease is more common in women than men. Moreover, the incidence of myasthenia gravis has increased globally, which is expected to drive the demand for effective treatments for the disease.

Furthermore, increase in the diagnosis of myasthenia gravis is expected to fuel the market growth. Myasthenia gravis is a rare and often misdiagnosed autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness and fatigue. The disease can be challenging to diagnose, as symptoms may be subtle or vary greatly from person to person. However, advancements in diagnostic techniques have led to more accurate and timely diagnosis of myasthenia gravis, which drives the market growth. The surge in the diagnosis of myasthenia gravis has increased the demand for effective treatments and fosters market growth. As more cases of myasthenia gravis are identified and diagnosed earlier, there is a greater need for effective treatments to manage the disease and prevent complications. This has led to increased investment in R&D of new and more effective treatments for myasthenia gravis.

Furthermore, the increase in diagnosis has led to greater awareness of the disease among patients and healthcare professionals. In addition, increase in number of drugs in clinical stages of development, focused on treatment of myasthenia gravis is anticipated to boost the growth of market. As the number of people affected by myasthenia gravis continues to increase, the demand for effective treatments rises, resulting in need for innovative therapies. This demand drives the pharmaceutical companies and research institutions to invest in the development of new treatments for the disease, with clinical trials serving as a critical tool for testing their safety and efficacy. Thus, upsurge in number of clinical trials focused on myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market by providing new and improved treatments for patients suffering from myasthenia gravis disease.

The myasthenia gravis treatment market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into cholinesterase inhibitors, immunosuppressants, monoclonal antibodies, intravenous immunoglobulin (IVIg), and others. On the basis of age group, the market is bifurcated into below 50 years and above 50 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global myasthenia gravis treatment market are: F. Hoffmann-La Roche Ltd., AstraZeneca, Novartis AG, Zydus Lifesciences Limited, Bausch Health Companies, Inc., CSL Limited, Grifols, S.A., Octapharma AG, Astellas Pharma Inc., and Kedrion, SpA. The key players have adopted strategies such as acquisition, agreement, strategic alliance, product approval, and expansion to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the myasthenia gravis treatment market analysis from 2022 to 2032 to identify the prevailing myasthenia gravis treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the myasthenia gravis treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global myasthenia gravis treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug class

  • Intravenous immunoglobulin
  • Others
  • Monoclonal antibodies

By Age group

  • Below 55 years
  • Above 55 years

By Distribution channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Astellas Pharma Inc.
    • AstraZeneca
    • Bausch Health Companies, Inc.
    • CSL Limited
    • F. Hoffmann-La Roche Ltd.
    • Grifols, S.A.
    • Kedrion, SpA
    • Novartis AG
    • Octapharma AG
    • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in demand of effective treatments for myasthenia gravis
      • 3.4.1.2. Surge in prevalence of myasthenia gravis
      • 3.4.1.3. Advancements in R&D of novel drugs
    • 3.4.2. Restraints
      • 3.4.2.1. Side effects and high cost associated with treatments for myasthenia gravis
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Monoclonal antibodies
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Intravenous immunoglobulin
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Below 55 years
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Above 55 years
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug store and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug class
    • 7.2.3. Market size and forecast, by Age group
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug class
      • 7.2.5.1.3. Market size and forecast, by Age group
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug class
      • 7.2.5.2.3. Market size and forecast, by Age group
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug class
      • 7.2.5.3.3. Market size and forecast, by Age group
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug class
    • 7.3.3. Market size and forecast, by Age group
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug class
      • 7.3.5.1.3. Market size and forecast, by Age group
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug class
      • 7.3.5.2.3. Market size and forecast, by Age group
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug class
      • 7.3.5.3.3. Market size and forecast, by Age group
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug class
      • 7.3.5.4.3. Market size and forecast, by Age group
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug class
      • 7.3.5.5.3. Market size and forecast, by Age group
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug class
      • 7.3.5.6.3. Market size and forecast, by Age group
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug class
    • 7.4.3. Market size and forecast, by Age group
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug class
      • 7.4.5.1.3. Market size and forecast, by Age group
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug class
      • 7.4.5.2.3. Market size and forecast, by Age group
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug class
      • 7.4.5.3.3. Market size and forecast, by Age group
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Rest of Asia-Pacific
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug class
      • 7.4.5.4.3. Market size and forecast, by Age group
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug class
    • 7.5.3. Market size and forecast, by Age group
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug class
      • 7.5.5.1.3. Market size and forecast, by Age group
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug class
      • 7.5.5.2.3. Market size and forecast, by Age group
      • 7.5.5.2.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Zydus Lifesciences Limited
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Novartis AG
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. AstraZeneca
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Bausch Health Companies, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. CSL Limited
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Grifols, S.A.
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Octapharma AG
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Astellas Pharma Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Kedrion, SpA
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. F. Hoffmann-La Roche Ltd.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance